Gadolinium Chelate Contrast Material in Pregnancy: Fetal Biodistribution in the Nonhuman Primate

Abstract

Purpose:To determine the extent to which gadolinium chelate is found in nonhuman primate fetal tissues and amniotic fluid at 19-45 hours after intravenous injection of a weight-appropriate maternal dose of the contrast agent gadoteridol. Materials and Methods:Gravid Japanese macaques (n = 14) were maintained as approved by the institutional animal care and utilization committee. In the 3rd trimester of pregnancy, the macaques were injected with gadoteridol (0.1 mmol per kilogram of maternal weight). Fetuses were delivered by means of cesarean section within 24 hours of maternal injection (range, 19-21 hours; n = 11) or 45 hours after injection (n = 3). Gadolinium chelate levels in the placenta, fetal tissues, and amniotic fluid were obtained by using inductively coupled plasma mass spectrometry. The Wilcoxon rank sum test was used for quantitative comparisons. Results:Gadoteridol was present in the fetoplacental circulation at much lower quantities than in the mother. At both time points, the distribution of gadolinium chelate in the fetus was comparable to that expected in an adult. The highest concentration of the injected dose (ID) was found in the fetal kidney (0.0161% ID per gram in the 19-21-hour group). The majority of the in utero gadolinium chelate was found in the amniotic fluid and the placenta (mean, 0.1361% ID per organ 6 0.076 [standard deviation] and 0.0939% ID per organ 6 0.0494, respectively). Data acquired 45 hours after injection showed a significant decrease in the gadolinium chelate concentration in amniotic fluid compared with that in the 19-21-hour group (from 0.0017% to 0.0007% ID per gram; P = .01). Conclusion:Amounts of gadolinium chelate in the fetal tissues and amniotic fluid were minimal compared with the maternal ID. This may impact future clinical studies on the safety of gadolinium contrast agent use in pregnancy.q RSNA, 2015

Gadolinium as an Emerging Microcontaminant in Water Resources: Threats and Opportunities

“…To determine the potential Gd 3+ fetal toxicity after maternal gadoteridol intravenous injection, Oh et al [209] obtained concentrations of the Gd chelate in nonhuman primate placenta, fetal tissues, and amniotic fluid. Compared to the maternal injected dose, the Gd complex concentrations in the fetal tissues and amniotic fluid were minimal, which may alleviate some concerns regarding MRI Gd chelate administration during pregnancy.…”

Magnetic resonance imaging for abnormally invasive placenta: the added value of intravenous gadolinium injection

“…An extensive literature review could not identify any fetal effect following intrauterine exposure . Although gadolinium crosses the placenta into the fetal circulation, to be excreted by the fetal kidneys into the amniotic fluid, a recent study in a nonhuman primate model demonstrated that minimal amounts of gadolinium are found in fetal tissue and amniotic fluid, compared with the dose injected into the mother …”

Gadolinium‐based contrast agents: A comprehensive risk assessment

“…33 Corroborating this theory, a study performed in gravid macaques showed the highest amniotic fluid concentration of GBCAs at 19-21 hours after maternal administration followed by a statistically significant decline at 45 hours. 34 In that study, the liver was the site of second greatest visceral GBCA accumulation (after the kidney), containing 0.0013% of the injected dose per gram of tissue at 45 hours postinjection. In contrast, only 0.00002% of injected GBCA dose was detectable within the fetal brain on a pergram basis at this same timepoint.…”

“…Once within the fetal circulatory system, GBCAs undergo renal clearance and enter the amniotic fluid via excretion from the urinary bladder, after which fetal swallowing is thought to result in gastrointestinal reabsorption . Corroborating this theory, a study performed in gravid macaques showed the highest amniotic fluid concentration of GBCAs at 19–21 hours after maternal administration followed by a statistically significant decline at 45 hours . In that study, the liver was the site of second greatest visceral GBCA accumulation (after the kidney), containing 0.0013% of the injected dose per gram of tissue at 45 hours postinjection.…”